ViaDerma, Inc. Provides a Corporate Update

LOS ANGELES, June 23, 2020 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink:VDRM), is pleased to provide this corporate update:

• ViaDerma has partnered with the ., to market a white label version of  which will be sold under the name BWell. Founded by former NFL star Jack Brewer, ’s portfolio of projects has included hundreds of public and private capital markets transactions, major event coordination, as well as partnerships with elite brands and influencers across multiple genres. 
• In addition to previously announced ongoing sales discussions, the Company has entered separate negotiations with representatives from the Middle East to explore the possibility of selling  and potentially other ViaDerma products in several Middle Eastern countries.
• The Company filed its Attorney Letter with Respect to Current Information with the OTC Markets in conjunction with its financial report and is making some minor amendments requested by OTC Markets. Upon completion of those amendments anticipated in the coming days ViaDerma is expected to return to a current filing status on OTC Markets.

Dr. Christopher Otiko, President of ViaDerma, said “I am very pleased with the progress we are making on several fronts. Medical sales are typically not quick to close and often take time to bring to fruition. We have been working on several transactions for some time and we believe some may now be in the final stages of negotiation. I hope to provide further announcements regarding those pending transactions in the near future.”

Additionally, the Company has received questions in recent days regarding Dr. Otiko’s association with The Wound Pros. The Wound Pros is a medical practice specializing in wound care in which Dr. Otiko is a cofounder. The Wound Pros is completely independent of ViaDerma. Possible future synergies between the companies may be explored down the road, though there are no collaborations at this time.

About ViaDerma, Inc.

ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas.

Any forecast of future financial performance is a “forward looking statement” under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment. Our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements.

For more information, visit: 

Contact information:

Investor Relations

Email: 

Phone: 310-374-6111